Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The prognosis for pts with PD-EP-NEC is poor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: McNamara M
Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,
Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Riechelmann R
Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,
Keywords: neuroendocrine, estrogen, progesterone, clinical trial,
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Isiangulova A, Khasanov R,
Keywords: neuroendocrine tumors, somatostatin analogues, target therapy, everolimus, systemic therapy,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,
Keywords: PDR001, immunotherapy, NET,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Yao J
Authors: Yao J, Fazio N, Pavel M, Strosberg J, Bergsland E,
Keywords: PDR001, immunotherapy, NET,